Research Paper Volume 16, Issue 6 pp 5618—5633
Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy
Figure 7. Expression of HOXC6, WT1, CD70, and OTP in 54 glioma cases with TERTp mutations. TERTp-mutant glioma samples from 54 glioma patients admitted to our hospital were divided into long- and short-term survival groups based on a survival cut-off of 15 months. (A) IHC scores for HOXC6, WT1, CD70, and OTP expression in glioma samples from patients in the long- and short-term survival groups. (B) Representative IHC images showing the expression of HOXC6, WT1, CD70, and OTP in glioma samples from patients in the long- and short-term survival groups. (C–F) Diagnostic value of HOXC6, WT1, CD70, and OTP for distinguishing long- and short-term survivors among glioma patients with TERTp mutations.